Micro Array Analysis in Preeclampsia

Public Assistance-Hospitals of Marseille (AP-HM)

Status: Unknown

Conditions: Preeclampsia

Treatments: Other: biopsy placentaire; Other: samples blood

Study type: Interventional

Funder types: Other

Identifiers

NCT01914809

2010-04

2010-A00633-36

Details and patient eligibility

About

Preeclampsia is a frequent pathology. His etiology is doubtful.

Targets :

The study target is to identify a risk of preeclampsia group obtained with transcriptom analysis from circulating peripheric cells.

Design:

Multidisciplinary study (Gynaecology-Obstetric, Immunology, North CIC).

The study of the transcriptional history of peripheral blood cells of 2patients groups:

• A patient group with a preeclampsia before 34 SA
• A patient group with a normal pregnancy paired on main confusion factors. Blood sampling will be collected at the diagnosis and 8 weeks after delivery.

Results and perspectives

• Obtain a transcriptionnal signature of preeclampsia
• To identify new mechanism of the disease
• Identification of a specific transcriptom analysis with the comparison after delivery For long-term, the target is to identify risk patient in order to conduct easily preventive clinical trials in preeclamsia (primary prevention) and to consider a specific follow-up for risk patients.

Enrollment: 40 estimated patients

Sex: Female

Ages: 18 to 40 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A prééclampsie (blood pressure superior to 140 mmHg and to 90 mmHg) and at least a cross of protein in the strip and/or more of 300mg / 24h after 20 LIMITED COMPANIES and before 34 limited companies.
• An informed consent signed by the patient will necessarily have to be obtained.
• Woman having been taken care during the pregnancy or at the time of the childbirth(delivery) by one of the participating teams to the current project.
• Caucasian Patient
• Wait primigeste and nullipare

Exclusion criteria

• Major Patient protected by the law.
• Patient deprived of freedom for administrative or judicial reasons.
• Patient not benefiting from a national insurance scheme.
• Refusal of the patient to participate in the study.
• Not Caucasian Patient
• Multipare Wait
• Multiple Pregnancy
• Existence of foetal deformation explaining a delay of growth or a foetal death in utero.
• Age 18 years and > 40 years.
• Absence of written consent or impossibility to receive the written consent (language or understanding).

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

group with a preeclampsia before 34 SA

Experimental group

Treatment:

Other: samples blood

Other: biopsy placentaire

group with a normal pregnancy

Other group

Treatment:

Other: samples blood

Other: biopsy placentaire